| A Study to Evaluate the Utilization, Effectiveness, and Quality of Life of Ozanimod in Participants With Ulcerative Colitis (NCT05382715) | Bristol-Myers Squibb | 2022-05-30 |
| A Study Investigating Oral Ozanimod (RPC1063) in Pediatric Participants With Moderate to Severe Active Ulcerative Colitis (NCT05076175) | Bristol-Myers Squibb | 2022-05-30 |
| Real World Data on Vedolizumab Concentration and Outcomes in Inflammatory Bowel Disease (IBD) Patients Switching From Intravenous (IV) to Subcutaneous (SC) Vedolizumab in University Hospital Center Osijek (NCT05504915) | Osijek University Hospital | 2022-05-01 |
| A Study on Administration Choices of Vedolizumab and Outcomes for Adults With Inflammatory Bowel Disease (IBD) (VARIETY - CROATIA AND SLOVENIA) (NCT04885920) | Takeda | 2022-02-22 |
| Protein and Magnesium in Ulcerative Colitis (NCT05271838) | University of Aarhus | 2022-02-08 |
| A Study on How Vedolizumab is Given and the Outcomes for Adults With Inflammatory Bowel Disease (VARIETY-Belgium) (NCT04959851) | Takeda | 2021-12-02 |
| VTX002 Versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis (NCT05156125) | Oppilan Pharma Ltd | 2021-11-30 |
| A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics (PD) of GSK3888130B in Healthy Participants (NCT05131971) | GlaxoSmithKline | 2021-11-01 |
| A Study of Vedolizumab in Adults in Real-World Practice (NCT04872491) | Takeda | 2021-10-22 |
| A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Ulcerative Colitis (UC) (NCT04779307) | Takeda | 2021-10-19 |
| A Long-term Extension Study of Ustekinumab in Pediatric Participants (NCT05092269) | Janssen Research & Development, LLC | 2021-10-18 |
| A Study in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) Receiving Vedolizumab in Real-World Practice in Switzerland (NCT04989907) | Takeda | 2021-09-08 |
| A Study of Moderate to Severe Inflammatory Bowel Disease, Including Ulcerative Colitis (UC) and Crohn's Disease (CD) (NCT04873700) | Takeda | 2021-08-30 |
| A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in Real-World Practice (NCT04890262) | Takeda | 2021-08-18 |
| A Study of LY3471851 in Adult Participants With Moderately to Severely Active Ulcerative Colitis (UC) (NCT04677179) | Nektar Therapeutics | 2021-03-22 |
| A Study of Ustekinumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis (UC) (NCT04630028) | Janssen Research & Development, LLC | 2021-03-17 |
| A Study of the Safety, Efficacy, and Biomarker Response of BMS-986165 in Participants With Moderate to Severe Ulcerative Colitis (NCT04613518) | Bristol-Myers Squibb | 2021-03-15 |
| De-escalation of Anti-TNF Therapy in Inflammatory Bowel Disease (NCT04646187) | University Medical Center Groningen | 2021-03-11 |
| Diet Intervention Treatment for Active Ulcerative Colitis (NCT04121806) | Mount Sinai Hospital, Canada | 2021-03-01 |
| Pharmacologic Weight Loss as Adjunct Therapy for Ulcerative Colitis in Obese Patients (NCT04721873) | University of California, San Diego | 2020-12-18 |
| Using Vedolizumab-800CW to Gain Insight Into Local Drug Distribution and Mucosal Target Cells in IBD Patients (NCT04112212) | University Medical Center Groningen | 2020-11-04 |
| Paricipant Preferences in the Treatment of Inflammatory Bowel Disease (IBD) in Europe (NCT04597905) | Takeda | 2020-10-21 |
| Study of Relationship Between Vedolizumab Therapeutic Drug Monitoring, Biomarkers of Inflammation and Clinical Outcomes (NCT04567628) | Takeda | 2020-10-05 |
| Physical Fitness Levels in Children and Adolescents With Chronic Inflammatory Bowel Disease (CIBD): Crohn's Disease, Ulcerative Colitis, Chronic Unclassified Colitis (NCT04647578) | University Hospital, Lille | 2020-09-01 |
| A Study of JNJ-66525433 in Healthy Participants and Participants With Ulcerative Colitis (NCT04457960) | Janssen Research & Development, LLC | 2020-07-01 |
| A Study of Kynteles Injection (Vedolizumab) in Adults With Moderate to Severe Ulcerative Colitis or Crohn's Disease or Chronic Pouchitis (NCT04799496) | Takeda | 2020-06-10 |
| Determination of the Optimal Treatment Target in Ulcerative Colitis (NCT04259138) | Alimentiv Inc. | 2020-02-18 |
| Study of Efficacy, Safety, and Tolerability of LYS006, in Patients With Mild to Moderate Ulcerative Colitis (NCT04074590) | Novartis Pharmaceuticals | 2020-02-03 |
| The Associations of Microribonucleic Acid Gene Polymorphisms With the Risk of Ulcerative Colitis (NCT06873711) | Second Affiliated Hospital of Wenzhou Medical University | 2020-01-01 |
| TITRATE (inducTIon for acuTe ulceRATivE Colitis) (NCT03937609) | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | 2019-09-04 |
| Tofacitinib Registry of Patients With Ulcerative Colitis in Germany (NCT04032756) | Ced Service GmbH | 2019-08-01 |
| To Evaluate Efficacy and Long-term Safety of Ozanimod in Japanese Subjects With Moderately to Severely Active Ulcerative Colitis (NCT03915769) | Celgene | 2019-06-03 |
| Safety, Tolerability, Efficacy and Dose-response of GSK2831781 in Ulcerative Colitis (NCT03893565) | GlaxoSmithKline | 2019-05-06 |
| Acupuncture in Pediatrics and Adolescents With Chronic Inflammatory Bowel Diseases (NCT04488198) | Medical University of Vienna | 2019-03-01 |
| A Study to Observe Vedolizumab and Anti-tumour Necrosis Factors (Anti-TNFs) Outcomes in Real-world Biologic Ulcerative Colitis (UC) and Crohn's Disease (CD) Participants (NCT03710486) | Takeda | 2019-02-19 |
| A Study Evaluating the Efficacy and Safety of ST-0529 in Subjects With Moderately to Severely Active Ulcerative Colitis (NCT03844932) | Sublimity Therapeutics Holdco Limited | 2019-01-24 |
| A Study to Evaluate Disease Control, Treatment Patterns, Burden of Disease and Quality of Life in Participants With Moderate to Severe Inflammatory Bowel Disease (IBD) (NCT03488030) | Takeda | 2018-12-12 |
| A Study of Efficacy and Safety of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (NCT03662542) | Janssen Research & Development, LLC | 2018-11-20 |
| A Study to Assess the Efficacy and Safety of Golimumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis (NCT03596645) | Janssen Research & Development, LLC | 2018-10-29 |
| BI 655130 Long-term Treatment in Patients With moderate-to Severe Ulcerative Colitis (NCT03648541) | Boehringer Ingelheim | 2018-10-29 |
| Optimization of Golimumab Treatment in Ulcerative Colitis (NCT03669029) | Hospital de Manises | 2018-10-01 |
| Prevention of Readmissions at IBD Centres of Excellence (NCT02931799) | Mount Sinai Hospital, Canada | 2018-10-01 |
| Real-world Effectiveness of Ustekinumab in Participants Suffering From Inflammatory Bowel Disease (Crohn's Disease or Ulcerative Colitis) With Extra-intestinal Manifestations or Immune-mediated Inflammatory Diseases (NCT03606499) | Janssen Cilag S.A.S. | 2018-09-26 |
| COlonic Salvage by Therapeutic Appendectomy. (NCT03912714) | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | 2018-08-24 |
| A Study to Evaluate Disease Control and Treatment Pattern in Participants With Moderate to Severe Inflammatory Bowel Disease (IBD) in Real Life Practice (NCT03532932) | Takeda | 2018-07-20 |
| One-year Persistence to Treatment of Participants Receiving Flixabi or Imraldi: a French Cohort Study (NCT03662919) | Biogen | 2018-07-02 |
| A Study to Evaluate the Safety and Efficacy of AJM300 in Participants With Active Ulcerative Colitis (NCT03531892) | EA Pharma Co., Ltd. | 2018-06-06 |
| Digital Holographic Microscopy: Evaluation of Histological Disease Activity in Patients With Ulcerative Colitis (NCT03464474) | University Hospital Muenster | 2018-04-01 |
| BI655130 (SPESOLIMAB) Induction Treatment in Patients With Moderate-to-severe Ulcerative Colitis (NCT03482635) | Boehringer Ingelheim | 2018-03-27 |
| Combined Nutritional Therapies for the Treatment of Ulcerative Colitis (NCT03444311) | AB Biotics, SA | 2018-03-08 |
| A Study to Determine the Pharmacokinetics (PK) of Single Intravenous (IV) Dose of Vedolizumab 300 Milligram (mg) in Healthy Adult Chinese Participants (NCT03329209) | Takeda | 2018-03-05 |
| To Evaluate the Efficacy and Safety of FE 999315 in Japanese Subjects With Mild to Moderate Active Ulcerative Colitis (NCT03412682) | Ferring Pharmaceuticals | 2018-03-02 |
| Fecal Microbiota Alterations in Steroid Refractory Active Colitis Ulcerosa (NCT03460847) | Medical University of Graz | 2018-03-01 |
| A Study to Assess the Effectiveness and Safety of Treatment With Vedolizumab in Adult Participants With Ulcerative Colitis (UC) or Crohn's Disease (CD) in Real Life (NCT03378388) | Takeda | 2018-02-13 |
| Postmarketing Vedolizumab Milk-Only Lactation Study in Lactating Women With Active Ulcerative Colitis or Crohn's Disease (NCT02559713) | Takeda | 2017-11-29 |
| Detection of Herpesvirus DNA (CMV, EBV, HHV-6 and HSV) in Colonic Tissue: Impact on Ulcerative Colitis Flare-up (NCT03172195) | Centre Hospitalier Universitaire de Saint Etienne | 2017-10-11 |
| Hyperbaric Oxygen Therapy for Ulcerative Colitis Flares (NCT03494764) | Dartmouth-Hitchcock Medical Center | 2017-09-07 |
| A Study to Assess Clinical Effectiveness and Safety of Vedolizumab Intravenous in Real World Clinical Practice in Ulcerative Colitis (UC) Korean Participants (NCT03535649) | Takeda | 2017-08-17 |
| Anti-tumor Necrosis Factor in Patients With Ulcerative Colitis in Clinical Remission: to Continue or Not? (NCT03011268) | Helse Møre og Romsdal HF | 2017-06-09 |
| A Study in Patients With Mild or Moderate Ulcerative Colitis Who Take a TNF Inhibitor. The Study Investigates Whether Bowel Inflammation Improves When Patients Take BI 655130 in Addition to Their Current Therapy (NCT03123120) | Boehringer Ingelheim | 2017-06-07 |
| MRI in Normal Ileal Pouches, and a Feasibility Study of Dynamic MRI Enema and Defaecating MRI Pouchography (NCT02925260) | London North West Healthcare NHS Trust | 2017-05-10 |
| Two Therapeutic Strategies for the Maintenance of Remission in Patients With Ulcerative Colitis (NCT03151525) | Istituto Clinico Humanitas | 2017-05-08 |
| Vedolizumab Intravenous (IV) Dose Optimization in Ulcerative Colitis (NCT03029143) | Takeda | 2017-03-29 |
| Sub-optimal Response to Anti-Tumor Necrosis Factor's in Inflammatory Bowel Disease in Emerging Markets (NCT03090139) | Takeda | 2017-03-28 |
| A Study to Observe the Safety and Efficacy of Vedolizumab in Biologically Naive Participants With Ulcerative Colitis (UC) or Crohn´s Disease (CD) (NCT02986724) | Takeda | 2017-01-04 |
| Inflammatory Bowel Disease in South Eastern Norway (NCT02727959) | Oslo University Hospital | 2017-01-01 |
| Beneficial and Harmful Effects of Azathioprine and Allopurinol Versus Standard Azathioprine Therapy for Patients With Ulcerative Colitis (NCT03101800) | Hvidovre University Hospital | 2016-12-14 |
| GSK2982772 Study in Subjects With Ulcerative Colitis (NCT02903966) | GlaxoSmithKline | 2016-11-15 |
| Phase 4, Vedolizumab-4002 Post-marketing, Disease-Drug-Drug Interaction Study (NCT02760615) | Takeda | 2016-11-01 |
| Open-label Extension Study to Assess Safety and Tolerability of LYC-30937-EC in Subjects With Active Ulcerative Colitis (NCT02764229) | Lycera Corp. | 2016-11-01 |
| Mercaptopurine Therapy in Ulcerative Colitis (NCT02910245) | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | 2016-11-01 |
| Safety, Efficacy, and Tolerability Study of PF-06480605 in Subjects With Moderate to Severe Ulcerative Colitis. (NCT02840721) | Telavant, Inc. | 2016-10-26 |
| Unraveling a Potential Connection Between Bilirubin Metabolism, Gut Microbiota and Inflammatory Bowel Diseases (NCT03841045) | Soroka University Medical Center | 2016-09-14 |
| CAsein GLycomacropeptide in Ulcerative Colitis - Anti-Inflammatory and Microbiome Modulating Effects (CAGLUCIM) (NCT02825914) | University of Aarhus | 2016-09-01 |
| Extended Access Program of Vedolizumab IV in Ulcerative Colitis and Crohn's Disease (NCT02743806) | Takeda | 2016-08-01 |
| An Efficacy and Safety Study of LYC-30937-EC in Subjects With Active Ulcerative Colitis (NCT02762500) | Lycera Corp. | 2016-07-01 |
| Study of a Monoclonal Antibody KHK4083 in Moderate Ulcerative Colitis (NCT02647866) | Kyowa Kirin, Inc. | 2016-06-01 |
| Initial Experience With a Novel Single-Balloon Enteroscopy System in Children With IBD (NCT02629211) | Smart Medical Systems Ltd. | 2016-06-01 |
| Effect of a Comprehensive Nutrition Support Product on the Nutritional Status of Adults With Inflammatory Bowel Disease (NCT02801240) | National University of Natural Medicine | 2016-06-01 |
| Improving the Health Care in Inflammatory Bowel Disease. (NCT02770599) | University Hospital of North Norway | 2016-05-15 |
| Anti-TNF Therapy for Refractory Colitis in Hospitalized Children (NCT02799615) | Children's Hospital Medical Center, Cincinnati | 2016-05-01 |
| A Study of Long-term Effects of Vedolizumab Subcutaneous in Adults With Ulcerative Colitis and Crohn's Disease (NCT02620046) | Takeda | 2016-04-15 |
| Home basEd faecaL calProtectin Measurements Predicting Adalimumab Induction Destiny (NCT02634060) | Universitaire Ziekenhuizen KU Leuven | 2016-03-31 |
| A Phase 2a, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Trial of IBD98-M (NCT02493712) | Holy Stone Healthcare Co., Ltd | 2016-01-01 |
| Localized Therapeutics for the Treatment of Gastrointestinal Disorders II (NCT02745678) | Stanford University | 2016-01-01 |
| Patient Centered Algorithms to Optimize the Inpatient Experience and Treatment of Ulcerative Colitis (NCT02569333) | Mount Sinai Hospital, Canada | 2016-01-01 |
| Efficacy and Safety of Vedolizumab Subcutaneously (SC) as Maintenance Therapy in Ulcerative Colitis (NCT02611830) | Takeda | 2015-12-18 |
| An Efficacy and Safety Study of Mongersen (GED-0301) in Subjects With Active Ulcerative Colitis (NCT02601300) | Celgene | 2015-12-14 |
| OTIS Vedolizumab Pregnancy Exposure Registry (NCT02678052) | Takeda | 2015-12-01 |
| Budesonide 9 mg Capsules in Active UC (NCT02550418) | Dr. Falk Pharma GmbH | 2015-10-01 |
| Aminosalicylic Acid Withdrawal Study in Long Standing Inactive Ulcerative Colitis (NCT02537210) | Chinese University of Hong Kong | 2015-09-01 |
| "Efficacy and Safety of Infliximab-biosimilar (Inflectra) Compared to Infliximab-innovator (Remicade) in Patients With Inflammatory Bowel Disease in Remission: the SIMILAR Trial" (NCT02452151) | Onze Lieve Vrouwe Gasthuis | 2015-08-01 |
| A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis (NCT02407236) | Janssen Research & Development, LLC | 2015-07-10 |
| An Open Label Phase 4 Study to Evaluate Efficacy of Early Versus Late Use of Vedolizumab in Ulcerative Colitis (NCT02646657) | Geert D'Haens | 2015-07-01 |
| An Efficacy and Safety Study of Vedolizumab Intravenous (IV) Compared to Adalimumab Subcutaneous (SC) in Participants With Ulcerative Colitis (NCT02497469) | Takeda | 2015-06-29 |
| Remote Ischemic Conditioning in Patients With Ulcerative Colitis (NCT02445365) | Odense University Hospital | 2015-05-01 |
| Correlation of Infliximab Levels With Outcomes in Ulcerative Colitis (NCT02438410) | Mayo Clinic | 2015-05-01 |
| Confocal Laser Endomicroscopy for Assessment of Mucosal Healing in Ulcerative Colitis (NCT02676817) | European Georges Pompidou Hospital | 2015-04-01 |
| Golimumab in Steroid-dependent Ulcerative Colitis: Induction and Maintenance of Clinical and Endoscopic Remission (NCT02412085) | Istituto Clinico Humanitas | 2015-03-01 |
| Correlation of Soluble Suppression of Tumorigenicity 2 (ST2) With Golimumab (MK-8259) Response in Participants With Ulcerative Colitis (UC) (MK-8529-022). (NCT02318667) | Merck Sharp & Dohme LLC | 2015-02-27 |